UNSPSC 51323203: Pirinixic acid

This classification denotes an organic carcinogen with the molecular formula C14H14ClN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86C4MRT55A, chemically known as 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid but generally known as pirinixic acid, which bears US NIH Compound Identifier 5694. European Medicines Agency schedules Pirinixic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09915MIG.

UNSPSC 51323203 Pirinixic acid is a Commodity code that state and local governments use to tag pharmaceutical procurement opportunities, though recent solicitation activity shows the code applied to broader emergency medical and prescription pharmaceutical supply chains rather than pirinixic acid specifically. State and local buying under this code span emergency life-support medications for fire rescue operations, direct-to-manufacturer prescription programs for health benefit plans, and multi-state cooperative purchasing agreements for generic and over-the-counter pharmaceutical products. Issuing bodies include city purchasing departments (Tampa), state health agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple jurisdictions including Oregon). The work is fundamentally pharmaceutical supply and distribution contracting with compliance requirements around FDA approval, cGMP certification, Drug Supply Chain Security Act adherence, expiration and shelf-life standards, and OSHA Safety Data Sheet documentation.

Recent activity shows geographic spread across Florida, Texas, Minnesota, and Oregon. Representative opportunities include the City of Tampa's sealed-bid procurement (26P00188) for Advanced Life Support Medications for Tampa Fire Rescue with a response deadline of April 8, 2026 and estimated contract value of $40,000.00; the Texas Health and Human Services Commission's Request for Information (HHS0017013) to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, posted April 3, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance's Request for Proposal (S1070000015802) for generic multi-source pharmaceuticals and OTC products across state and local facilities, with proposals due March 26, 2026 and contract effective July 1, 2026. The Tampa procurement includes a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount not to exceed $10,000. Recent opportunities emphasize fixed pricing models, authorized-wholesaler distribution, multi-year terms with renewal options, and performance penalties for compliance failures.